HAON Life Science

🚨 𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐬 𝐅𝐢𝐫𝐬𝐭 𝐌𝐒𝐂 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲! Mesoblast achieves a historic milestone with FDA approval of Ryoncil®, the first-ever mesenchymal stromal cell (MSC) therapy in the U.S. Ryoncil is approved for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients aged 2 months and older. 𝐊𝐞𝐲 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: 👉 TreatsSR-aGvHD, which has high mortality and limited treatment options. 👉 Efficacy: In pivotal trials, 70% of patients with severe disease responded within 28 days—a predictor of long-term survival. 👉 Milestone: First FDA-approved MSC therapy, showcasing the feasibility of cell-based treatments for inflammatory diseases and FDAs door opens. Interestingly, RYONCIL uses bone marrow-derived MSCs to suppress T-cell activation and modulate immune responses, reducing severe inflammation. Congratulations Mesoblast and team. Superb end to the year! #celltherapy #immunology #cellandgenetherapy #CGTweekly

🚀 Exciting News from the EIT Health Fast Track Programme! 🚀 Under our Fast Track initiative, 10 promising start-ups from our portfolio received exclusive mentoring support from our experts and bypassed the EIC Accelerator's initial application stage, advancing directly to the full application process. 🌟 🎉 Congratulations to our selected start-ups: Exhalation Technology Ltd NIB biotec Cellprothera HAON Life Science Corify EFM SensePilot Scicake CheckEye Innocens The EIC Accelerator supports innovative companies in developing and scaling up game-changing solutions, offering: 💶 Grant funding of up to 2,5 million € 💼 Equity investments of up to €10 million €, managed by the EIC Fund ✨ Are you ready to be part of the next success story? Learn more about our Fast Track Programme here: https://lnkd.in/eYyBJnkW

During #ScienceWeek, #HAON agree with the article below, Ireland and also Europe have a very significant opportunity to lead on regenerative cell therapy development.  #HAON's placental cell platform generates allogeneic (off-the -shelf) endothelial colony forming cells (ECFC) that pass the blood-brain barrier and home to sites of injury. We believe that regeneration has the potential to advance care for diseases with limited treatment options by changing the paradigm from small steps to transformational change. To learn more about our work at HAON, please check out a recent interview with the founders: https://lnkd.in/eBGZgjqx #ScienceWeek #ResearchIreland #HAON #EnterpriseIreland #Celltherapy #AdvancedTherapies

We also had the opportunity to sit down with Moayed Hamza and Mark O’Neill FCA from HAON Life Science, which develops investigational allogeneic candidates for neurologic, rare and other serious diseases. Their first focus indication is neonatal HIE – a type of newborn brain injury – that according to Nature has an incidence that varies between 1 and 3 per 1000 live births in developed countries and 2.3 to 30.6 per 1000 live births in developing countries. Yet, there are no current treatments available aside from cooling. Hamza and O'Neill tells BioStock that their platform is applicable in multiple neurodegenerative diseases, but that they aim for a first approval in neonatal HIE due to its high unmet medical need, lack of competition in the market and thus presents an opportunity for accelerated approval. Hear more about their progress in our interview!

We're entering new territory at CergenX! Our first product, the CergenX Wave device, is currently being tested on newborns in a hospital environment as part of a Feasibility Study. This non-interventional, observational study is designed to assess the usability of the device. The Feasibility Study is a key element of CergenX's DTIF partnership with the INFANT Research Centre at University College Cork. The study is part of the CergenX-led consortium, which was awarded €6.7m in non-dilutive grant funding last year from Enterprise Ireland and DTIF. Recruitment for the study is progressing well, with dozens of newborns already tested. This marks a significant milestone for CergenX, elevating the company to the next level. In a short period of time, the team has transformed a promising idea into a fully realised device that is now deployed in a busy hospital setting. Wave is poised to make a meaningful impact on newborns, their families, and healthcare professionals. The entire team at CergenX is proud of this achievement—the result of 18 months of hard work and perseverance. Our special thanks are extended to the team at INFANT Research Centre and Cork University Maternity Hospital (CUMH) for their instrumental role in launching and maintaining the study, as well as to the parents who consented to their newborns participating. Cork University Hospitals Group #MedTechInnovation #BrainInjury #AiForGood

It's #WorldCerebralPalsyDay 💚 ⁉ Did you know, an estimated 150 babies receive a Cerebral Palsy(CP) diagnosis in Ireland each year, and an estimated 3,000 children and young people and 9,500 adults are living with CP in Ireland? It is in fact the most common lifelong physical disability in Ireland. Earlier this year, we launched a new ground-breaking five-year research programme called ELEVATE - led by INFANT at University College Cork, partnered with Royal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences and Trinity College Dublin, as well as the tertiary-level maternity hospitals. ELEVATE is co-funded by Research Ireland (formerly SFI) and the Cerebral Palsy Foundation (CPF), and aims to improve the prevention, detection and treatment of early brain injury and cerebral palsy in Ireland. By fostering collaboration between clinical, academic, and industry partners, as well as involving individuals with CP and their families from the outset, Ireland is set to become a global leader in CP research and care. Ultimately this programme aims to provide hope and better outcomes for children and families impacted by CP. Read more about #ELEVATE here: https://lnkd.in/egPrWiK4

The HOUSE PASSED THE GIVE KIDS A CHANCE ACT, including the CREATING HOPE REAUTHORIZATION ACT! Today, Monday September 23, 2024, at 4:00 pm, the U.S. House of Representatives passed the Give Kid a Chance Act, HR 3433. The Give Kids a Chance Act ensures that kids with cancer will have studies of combinations of new cancer drugs. This is important because finding new combinations of cancer drugs is the best way to find new cures for kids. The Give Kids a Chance Act also the Creating Hope Reauthorization Act, reauthorizing the priority review voucher program, an incentive program that has resulted in over 60 new drugs for seriously ill kids. Vouchers sell for about $100 million. The Innovations in Pediatric Drugs Act is also part of the Give Kids a Chance Act, increasing funding for pediatric clinical studies at the National Institutes of Health and imposing monetary penalties when companies fail to complete their required pediatric drug studies. YOU DID IT. YOU SPOKE AS THE VOICES OF CHILDHOOD CANCER AND CONGRESS HEARD. We have more steps to go: passage of the Give Kids a Chance Act in the Senate and then signature by the President. But we have reached a critical milestone. Let’s get back to work. Let’s give kids with cancer hope. Let’s give kids with cancer a chance.

No baby who qualifies for therapeutic hypothermia should be missed. #ArtificialIntelligence may help achieve that goal by finding potential candidates by 1 hour after delivery using AS at 1 min & 5 min, postnatal pH, base deficit, & lactate https://lnkd.in/ge36B7DD #nicu #neonatal #HIE #hypoxicischemicencephalopathy

🎉 Celebrating 10 Years of INFANT 💜 Curious to learn more about INFANT? Take just 2 minutes to discover how this research centre at UCC has evolved over the past decade. As we celebrate 10 years of innovation, we’re proud to reflect on how INFANT's research has not only advanced maternal and child healthcare in Ireland but has also garnered recognition as a global leader in innovative research and transformative healthcare solutions. “INFANT has grown tremendously in scale, ambition, and research excellence over the past decade. Our team’s dedication has led to transformative international breakthroughs that positively impact the lives of babies, children, and families worldwide every day.” – Prof Geraldine Boylan, INFANT Director. 📽️ Watch the video below for a snapshot, and if you’d like to see more, check out the full version here: https://lnkd.in/ePCB3UzB 🎥 Video by Waking Dreams Media #INFANT10Years #MaternalHealth #ChildHealth #ResearchInnovation #UCCResearch #Healthcare #GlobalImpact

HAON team update: Dr. Michael Creane (PhD) has joined HAON as Translational Research Manager. Michael (Mikey), previously Strategic Lead at the Centre for Cell Manufacturing Ireland, joins with significant cell therapy expertise and was a Research Fellow at the Regenerative Medicine Institute at University Galway. Congratulations Mikey Creane on the new position and welcome onboard. #HAON #healthcareinnovation #neurodegenerativediseases #hopeforhie #neonatology #seriesa